SR-9009 Powder 1g

Description

SR-9009 Powder — Research Overview

SR-9009 (Stenabolic) is a synthetic Rev-erbα and Rev-erbβ agonist developed by the Scripps Research Institute. Rev-erb proteins are nuclear receptors that function as master regulators of the circadian clock, lipid metabolism, and mitochondrial biogenesis. SR-9009 is mechanistically distinct from SARMs — it does not bind the androgen receptor — but is grouped with them commercially due to similar research applications in body composition models.

Mechanism of Action

SR-9009 activates Rev-erbα/β, which suppress the expression of BMAL1 and Clock genes — key components of the circadian transcription-translation feedback loop. This disrupts the normal circadian oscillation, producing constitutive activation of metabolic gene programs normally only active during the active phase. The result in rodent models: increased mitochondrial density in skeletal muscle, enhanced fatty acid oxidation, reduced lipid and glucose synthesis in the liver, and increased basal metabolic rate irrespective of activity level.

Research Applications

Primary research contexts: circadian biology (clock gene manipulation), metabolic syndrome (insulin resistance, dyslipidaemia, NAFLD models), inflammatory disease (Rev-erb regulates NF-kB-mediated inflammation), and cardiovascular research (atherosclerosis, cardiac hypertrophy models). Fang et al. (Nature Medicine, 2014) demonstrated SR-9009 reduces atherogenic lipid profiles and atherosclerotic plaque in LDL receptor–deficient mice — a frequently cited reference study.

Powder Format for Research

Powder is essential for circadian research requiring precise timed dosing and in vitro cell culture studies. Soluble in DMSO (≥50mg/mL). Standard in vivo: 100mg/kg/day IP injection or oral gavage in mouse studies.

Purity: ≥98% (HPLC verified) | Format: Lyophilised powder | Quantity: 1g

For research use only. Not for human consumption.